AbbVie reported a third-quarter beat driven by strength in immunology and neuroscience, raising full-year profit guidance. Management said it has room for additional acquisitions but prefers bolt-on deals rather than another large megamerger after the company’s prior acquisition of Allergan. The company posted Q3 sales of $17.4 billion and EPS of $3.82, and it lifted full-year EPS guidance. Immunology franchises including Skyrizi and Rinvoq contributed to the upside, alongside a neuroscience portfolio supported by growth in drugs such as Vraylar and migraine therapies. Chief executive Rob Michael indicated that near-term deal strategy would focus on incremental portfolio additions—an approach investors typically view as lower execution risk while maintaining capital efficiency.